Psychopharmacology in Renal Impairment

← Back to Chapters

The kidney is the exit door for a defined subset of psychotropics — and for the active metabolites of several more. When that door narrows, the drugs that leave the body by that route accumulate, while the many psychotropics cleared by the liver are largely unaffected. Good prescribing in renal impairment is therefore less about memorizing a hundred dose tables and more about a single sorting question: does this drug, or its active metabolite, depend on the kidney to leave the body? This chapter builds that framework, then applies it drug class by drug class, with the specific agents that need reduction, the ones that need avoiding, and the ones you can reach for with confidence — including the special cases of lithium, gabapentin and pregabalin, and the patient on dialysis.

Why renal impairment changes psychopharmacology

Chronic kidney disease alters drug handling through several mechanisms at once, and it helps to keep them separate because they push in the same direction — toward higher exposure and greater sensitivity.

Reduced excretion is the dominant effect. For any drug (or active metabolite) that leaves the body predominantly through glomerular filtration or tubular secretion, a fall in glomerular filtration rate directly prolongs half-life and raises steady-state concentration on repeated dosing. This is straightforward accumulation, and it is the reason a "normal" dose can become a toxic dose over days to weeks.

Uremia changes pharmacodynamics, not just pharmacokinetics. The uremic milieu is associated with a more permeable blood–brain barrier and heightened CNS sensitivity to sedatives and drugs with central effects, so patients often respond to — and develop side effects from — lower concentrations than their otherwise-healthy counterparts. Uremia also displaces acidic drugs from albumin (raising free fraction) and, conversely, the reduced albumin of nephrotic syndrome lowers protein binding further.

Fluid shifts move the target. Volume overload, diuresis, and the intravascular volume swings around a dialysis session change the volume of distribution and, for lithium especially, can move a stable level into a toxic or subtherapeutic range within hours.

Dialysis adds a second, intermittent clearance pathway. Small, water-soluble, minimally protein-bound drugs (lithium, gabapentin, pregabalin, topiramate) are efficiently removed by hemodialysis; large, lipophilic, highly protein-bound drugs (most antipsychotics and antidepressants) are not. Whether a drug is dialyzed determines both its toxicity profile and the timing of dosing around sessions.

The core principle: sort by route of elimination

Rather than treating every drug as a special case, sort your formulary into three bins. This single step resolves the majority of clinical decisions before you ever open a reference.

Bin 1 — renally eliminated parent drugs. Lithium, gabapentin, pregabalin, and topiramate are the psychiatric agents most dependent on the kidney for removal. These need the largest reductions and the most monitoring, and several are dialyzable.

Bin 2 — hepatically metabolized, but with renally cleared active metabolites. This is the bin that catches people out. Risperidone is metabolized to paliperidone (9-hydroxyrisperidone), which is renally excreted; paliperidone given as its own drug is even more renally dependent. Bupropion is hepatically metabolized but its active metabolite hydroxybupropion is renally cleared and accumulates (a seizure-threshold concern). Venlafaxine's active metabolite O-desmethylvenlafaxine (desvenlafaxine) is renally cleared. The parent looks "hepatic," but the clinically active moiety is not.

Bin 3 — hepatically metabolized with inactive metabolites. Sertraline, haloperidol (<1% excreted unchanged), aripiprazole, olanzapine, quetiapine, asenapine, and ziprasidone show little clinically significant pharmacokinetic change in renal impairment. These are your workhorses — though "no dose change" never means "no clinical caution" (QT, sedation, and orthostasis still matter).

Drug-by-drug guidance

The table below consolidates the practical adjustments. Thresholds are expressed as estimated GFR / creatinine clearance in mL/min; they are starting points for individualized dosing and monitoring, not rigid rules, and manufacturer labeling should be checked for any specific agent.

Lithium in chronic kidney disease

Lithium deserves its own section because every property that makes it therapeutically useful also makes it uniquely hazardous in renal disease. It is a small monovalent cation, not protein-bound, not metabolized, and handled almost entirely by the kidney — filtered at the glomerulus and reabsorbed in the proximal tubule in competition with sodium.

The bidirectional problem. Lithium can cause chronic kidney disease (nephrogenic diabetes insipidus and, over years, chronic tubulointerstitial nephropathy), and existing kidney disease makes lithium dangerous to dose. In a patient with established renal impairment, reduced clearance means a standard dose accumulates toward toxicity, while volume depletion — from dehydration, vomiting, diuresis, or a low-sodium state — increases proximal reabsorption and can precipitate toxicity even without a dose change.

Practical use. Lithium is relatively contraindicated in significant CKD and contraindicated in acute kidney injury. When it is genuinely necessary (for example, a patient whose bipolar illness has only ever responded to lithium), it demands lower doses, more frequent level checks, tight attention to volume and sodium status, and a clear plan for holding the drug during any acute illness. Because lithium is fully dialyzable, hemodialysis is both the treatment for severe toxicity and, in dialysis-dependent patients, a dosing strategy: give a single dose after each dialysis session and check the level before the next.

Gabapentinoids: the most common avoidable toxicity

Gabapentin and pregabalin are prescribed heavily for neuropathic pain, anxiety, and sleep — often by non-psychiatrists — and both are almost entirely renally excreted and readily dialyzed. Standard doses in a patient with even moderate CKD accumulate to produce sedation, dizziness, ataxia, myoclonus, and frank encephalopathy that is frequently mistaken for a primary neurologic or psychiatric deterioration. The corrective is dramatic dose reduction proportional to GFR, low starting doses, and post-dialysis supplementation in dialysis patients. When a CKD patient on a gabapentinoid presents with new confusion or falls, dose-related toxicity should be near the top of the differential.

The patient on dialysis

Two questions organize dosing in dialysis: is the drug removed by the dialyzer, and if so, when should it be given relative to the session? Dialyzable agents (lithium, gabapentin, pregabalin, topiramate) are typically given as a single dose after dialysis, so the just-administered dose is not immediately stripped out. Non-dialyzable agents (most antipsychotics and antidepressants, which are lipophilic and highly protein-bound) are dosed on their own schedule irrespective of sessions, but at the reduced steady-state dose appropriate to the residual renal function. Across the board, the interdialytic volume swings argue for conservative dosing and for anchoring decisions to measured levels wherever a therapeutic range exists.

For the broader principles behind these adjustments, see the Pharmacokinetics chapter; for the psychiatric syndromes that accompany organ failure itself, see Psychiatric Changes in Severe Organ Dysfunction. The companion special-population chapters on hepatic impairment, malabsorption & short gut, and long QT syndrome extend the same drug-selection logic to other medically complex patients.

References & Further Reading

1. Cohen LM, et al. Renal disease. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry.
2. Levy NB, Cohen LM. Psychopharmacology in patients with renal insufficiency and on dialysis. Adv Chronic Kidney Dis.
3. When to adjust the dosing of psychotropics in patients with renal impairment. Current Psychiatry. (MDedge review of manufacturer renal dosing.)
4. Baghdady NT, et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther.
5. Nagler EV, et al. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review. Nephrol Dial Transplant.
6. Cerqueira RO, et al. Practical guidance on lithium in patients with impaired renal function. Bipolar Disord.

This chapter is an educational review for clinicians and trainees. Dose thresholds are starting points for individualized care and must be checked against current product labeling and institutional protocols; it is not a substitute for clinical judgment.